Literature DB >> 15987828

Chronic morphine up-regulates G alpha12 and cytoskeletal proteins in Chinese hamster ovary cells expressing the cloned mu opioid receptor.

Heng Xu1, Xiaoying Wang, Darin Zimmerman, Emily S Boja, Jiabei Wang, Edward J Bilsky, Richard B Rothman.   

Abstract

A growing body of literature indicates that chronic morphine exposure alters the expression and function of cytoskeletal proteins in addition to the well established interactions between mu opioid receptors and G proteins. In the present study, we hypothesized that chronic morphine alters the expression and functional effects of G alpha12, a G protein that regulates downstream cytoskeletal proteins via its control of RhoA. Our results showed that chronic morphine treatment decreased the expression of G alpha i2 (64%) and G alpha i3 (60%), had no effect of G alpha o, and increased G alpha12 (66%) expression in Chinese hamster ovary (CHO) cells expressing the cloned human mu opioid receptors (hMOR-CHO cells) but not in cells expressing a mutant mu opioid receptor that do not develop morphine tolerance and dependence (T394A-CHO cells). Morphine treatment had no significant effect on PAR-1 thrombin receptor-activated G protein activity, as measured by thrombin-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate binding. Chronic morphine treatment significantly enhanced thrombin-stimulated RhoA activity and thrombin-stimulated expression of alpha-actinin, a cytoskeletal anchoring protein, in hMOR-CHO cells. Proteomic analysis of two-dimensional gel spots prepared from hMOR-CHO cells showed that morphine treatment affected the expression of a number of proteins associated with morphological changes. Up-regulation of G alpha12 and alpha-actinin by chronic morphine was also observed in mouse brain. Viewed collectively, these findings indicate, for the first time, that chronic morphine enhances the G alpha12-associated signaling system, which is involved in regulating cellular morphology and growth, supporting other findings that chronic morphine may alter cellular morphology, in addition to cellular function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987828     DOI: 10.1124/jpet.105.089367

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.

Authors:  Heng Xu; Xiaoying Wang; John S Partilla; Kristen Bishop-Mathis; Tova S Benaderet; Christina M Dersch; Denise S Simpson; Thomas E Prisinzano; Richard B Rothman
Journal:  Brain Res Bull       Date:  2008-06-04       Impact factor: 4.077

Review 2.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

3.  Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels.

Authors:  Joseph N Brown; Gabriel M Ortiz; Thomas E Angel; Jon M Jacobs; Marina Gritsenko; Eric Y Chan; David E Purdy; Robert D Murnane; Kay Larsen; Robert E Palermo; Anil K Shukla; Theresa R Clauss; Michael G Katze; Joseph M McCune; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2012-05-11       Impact factor: 5.911

4.  Global changes in the rat heart proteome induced by prolonged morphine treatment and withdrawal.

Authors:  Zdenka Drastichova; Jitka Skrabalova; Petr Jedelsky; Jan Neckar; Frantisek Kolar; Jiri Novotny
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

5.  Regulation of mammalian MOR-1 gene expression after chronic treatment with morphine.

Authors:  Rose V Prenus; Ebens Luscar; Zhi-Ping Zhu; Ramesh B Badisa; Carl B Goodman
Journal:  Int J Mol Med       Date:  2012-09-19       Impact factor: 4.101

6.  Morphine as a Potential Oxidative Stress-Causing Agent.

Authors:  Jitka Skrabalova; Zdenka Drastichova; Jiri Novotny
Journal:  Mini Rev Org Chem       Date:  2013-11       Impact factor: 2.495

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.